PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
- 25 January 2011
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 107 (3) , 477-485
Abstract
What’s known on the subject? and What does the study add? So far we know that ERG rearrangements and PTEN deletions interact to induce prostate cancer in transgenic mice. The study confirms that an association also exists between the two genetic aberrations in human prostate cancer, as there is increased incidence of PTEN deletions in cases with ERG rearrangements. OBJECTIVE: To investigate the interaction between, and significance of, ERG gene rearrangements and PTEN genomic deletions in relation to the development and progression of prostate cancer (PCA). PATIENTS AND METHODS: We interrogated an initial cohort of 220 men with localized PCA using fluorescence in situ hybridization for ERG rearrangements and PTEN genomic deletions. RESULTS: The incidences of ERG rearrangements and PTEN deletions in PCA were significantly higher than in high‐grade prostatic intra‐epithelial neoplasia (HGPIN) and benign prostate tissue ( P < 0.001). ERG rearrangements and PTEN deletions were detected in 41.9 and 42.6% of patients’ tumours, respectively. ERG rearrangements were never detected in benign prostate tissue, while PTEN aberrations were present at a basal level of 4.6%. PTEN hemizygous deletions showed higher frequency than homozygous deletions within each diagnostic category from benign prostate tissue to HGPIN and PCA ( P ≤ 0.001). Furthermore, in 29 patients where all three tissues were available, PTEN genomic aberrations in PCA were significantly different from those in benign tissue ( P = 0.005) and HGPIN ( P = 0.02), reflecting the accumulation of genomic aberrations in the early stages of disease progression. Within this cohort, 71.4% of homozygous and 44.2% of hemizygous PTEN deletions occurred simultaneously with ERG rearrangements ( P ≈ 0). Stratified according to Gleason score (GS), hemizygous PTEN deletions across various GS groups were observed at a higher frequency than homozygous deletions. However, PTEN homozygous deletions showed positive trends with higher GS, increasing in poorly differentiated PCA (GS 8–10) in comparison to moderately and well differentiated tumours (GS 6 and 7). CONCLUSION: We show significant association between ERG gene rearrangements and PTEN genomic aberrations in subset of PCA. Our analysis also provides further support for the observation that homozygous PTEN deletions can occur within the subset of HGPIN lesions, and shows accumulating genetic aberrations with disease progression, evidenced by higher detection in PCA than in HGPIN and more PTEN homozygous deletions in GS 8–10 than in 6–7.Keywords
This publication has 43 references indexed in Scilit:
- Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progressionLaboratory Investigation, 2009
- Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- Distinct genomic aberrations associated with ERG rearranged prostate cancerGenes, Chromosomes and Cancer, 2009
- Is PTEN loss associated with clinical outcome measures in human prostate cancer?British Journal of Cancer, 2008
- Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate CancerJNCI: Journal of the National Cancer Institute, 2008
- FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 2007
- Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerOncogene, 2007
- Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancersJournal of Clinical Pathology, 2007
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005